Embed Size (px)
Citation preview
1st 2nd
3rd
Lytix Biopharma AS | P.O. Box 6447 | NO-9294 Tromsø, Norway | E-mail: [email protected] | Phone: +47 77 67 55 00 | Fax: +47 77 67 55 01
BackgroundLTX-315 is a membrane active host-defence peptide representing a novel oncolytic treatment principle applied as intralesional therapy.
AimTo investigate whether LTX-315 induce abscopal effect in a novel rat mescenhymal three-tumor sarcoma model (rTMSC)
Tumor cells were inoculated s.c. at Day -5 on right flank (1st lesion) and at Day 0 on contralateral flank (second lesion) and i.p. (third lesion) in syngeneic PVG rats. The 1st lesion was treated with 1 mg LTX-315 once daily for 7 subsequent days (days 3 – 9). Representative whole-body bioluminescence images of LTX-315 treated and non treated lesions are presented.
Cured animals were re-challenged both s.c. and i.p with rTMSCs eight months later.
Conclusions
• Here we show for the first time that intralesional treatment of one single lesion with LTX-315 (OncoporeTM) is sufficient to cure animals with disseminated tumors.
• Systemic and long lasting protective immune responses was obtained in LTX-315 cured animals
• LTX-315 represents a novel intralesional therapeutic strategy with potential to induce clinical responses in metastatic diseases.
• A phase 1/2a study is in progress with LTX-315.
ReferencesCamilio et al., Cancer Immunol Immunther, 2014.Berge G et al., Cancer Immunol Immunther, 2010.
LTX-315 treatment induces complete and specificregression of dissaminated tumors in a novel mesenchymal three tumor modelKVALHEIM G.1, WANG MY.1, NESTVOLD J.2, CAMILIO CA.3, ROLSTAD B.2, SVEINBJØRNSSON B.3,AREFFARD A4 AND REKDAL Ø4
Oslo University Hospital – Norwegian Radium Hospital1, University of Oslo2, University of Tromsø3, Lytix Biopharma4
NH
O
NH2
NH
O
NH
O
N
NH
O
NH2
NH
O
NH2
NH
O
NH
NH
O
NH2
O
NH
O
NH
NH2
NH2
NH2
OH
O
n
Figure 1. Chemical structure of LTX-315
Figure 2. Study design of the three-tumor model
Figure 3. LTX-315 eradicates treated and non-treated lesions in the three-tumor rTMSc model
Figure 4. LTX-315 induce long term protective immune responses
3 6 9 14 19 26DAY
5 12 18 5 12 18
LTX-315 treated lesion
Treatment of the 1st lesion with 1 mg daily for 7 days
left flank
i.p.
+
3 6 9 14 19 26
2nd non-treated s.c. lesion 3rd non-treated i.p. tumor
3 6 9 14 19 26
Luminescence(p/s/cm2/sr)
Controlsn=6
Controlsn=6
LTX-315n=6
LTX-315n=6
Days postre-challenge
D-5 D 0 D3 D91st2nd
3rd
s.c tumors i.p tumors
